In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
Dell Technologies' Open Source Organization Releases the latest Version of REX-Ray as the First Project to Support Universal Container Storage Interface
From the debut of the RICOH Pro VC40000 to Neon Pink Toner to Clickable Paper, Ricoh's commitment to solving customer challenges is on full display in Booth 2022
New Data Show Promising Results and Support Continued Clinical Development,Highlights Success of Interrogative Biology Platform to Advance Potential New Treatment Options for Cancer Patients
57% of insurance CEOs see technological disruption as an opportunity rather than a threat, 82% looking to disrupt the sector rather than be disrupted by competitors
New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive Disease and Experience Excellent Five-year Survival without Chemotherapy
-- Preliminary results from subgroup analysis of ongoing phase 1 study demonstrate a 32 percent overall response rate and 82 percent disease control rate with DS-8201 in HER2-expressing metastatic solid tumors such as colon cancer, non-small cell lung cancer and other tumor types
29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer
- Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study
- Quality of life findings follow presentation of positive results at ASCO 2017 in which lenvatinib was the first systemic therapy to demonstrate non-inferiority to sorafenib in overall survival in first-line treatment of patients with unresectable HCC
- Median PFS for patients on combination of binimetinib (45 mg) plus encorafenib (300 mg) was 12.9 months versus 9.2 months for patients on encorafenib (300 mg) -